Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK clinical programs — 176 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
493
Drugs
98
Patents
837
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Regeneron UK projects

176 ClinicalTrials.gov programs sponsored by Regeneron UK.

Regeneron UK has 176 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

176 programs

Clinical programs

Page 1 of 4

  1. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  2. ALN-CFB

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  3. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  4. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  5. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  6. ALN-PNP

    Regeneron UK Limited

    Healthy Volunteers

    phase 2 small molecule active

    1 trial

  7. ALN-SOD

    Regeneron UK Limited

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  8. ARD6122

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial

  9. ARD6123

    Regeneron UK Limited

    Pulmonary Diseases

    phase 2 small molecule completed

    1 trial

  10. Aflibercept

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 2 small molecule completed

    1 trial

  11. Aflibercept

    Regeneron UK Limited

    Advanced Carcinoma

    phase 2 small molecule terminated

    1 trial

  12. Aflibercept

    Regeneron UK Limited

    Radiation Retinopathy

    phase 2 small molecule active

    1 trial

  13. Alirocumab

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 2 small molecule on hold

    1 trial

  14. Alirocumab

    Regeneron UK Limited

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  15. Alirocumab and Cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 other active

    1 trial

  16. Aspirin Challenge

    Regeneron UK Limited

    Aspirin-exacerbated Respiratory Disease

    phase 2 small molecule completed

    1 trial

  17. BNT111

    Regeneron UK Limited

    Melanoma Stage III

    phase 2 mab completed

    1 trial

  18. BNT116

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. CMP-001

    Regeneron UK Limited

    Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule terminated

    1 trial

  20. Capecitabine

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  21. Cemiplimab

    Regeneron UK Limited

    HPV-Related Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. Cemiplimab

    Regeneron UK Limited

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  23. Cemiplimab

    Regeneron UK Limited

    NSCLC

    phase 2 small molecule active

    1 trial

  24. Cemiplimab

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  25. Cemiplimab

    Regeneron UK Limited

    Hepatitis B Virus

    phase 2 mab terminated

    1 trial

  26. Cemiplimab

    Regeneron UK Limited

    HIV Infections

    phase 2 mab terminated

    1 trial

  27. Cemiplimab

    Regeneron UK Limited

    Basal Cell Carcinoma (BCC)

    phase 2 small molecule active

    1 trial

  28. Cemiplimab

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  29. Cemiplimab

    Regeneron UK Limited

    Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  30. Cemiplimab

    Regeneron UK Limited

    Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  31. Cemiplimab

    Regeneron UK Limited

    Locally Recurrent Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  32. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  33. Cemiplimab

    Regeneron UK Limited

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  34. Cemiplimab

    Regeneron UK Limited

    Colon and Rectal Cancer

    phase 2 small molecule active

    1 trial

  35. Cemiplimab

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  36. Cemiplimab

    Regeneron UK Limited

    High-Grade Glioma (HGG)

    phase 2 small molecule active

    1 trial

  37. Cemiplimab

    Regeneron UK Limited

    Colo-rectal Cancer

    phase 2 small molecule active

    1 trial

  38. Cemiplimab

    Regeneron UK Limited

    Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  39. Cemiplimab

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  40. Cemiplimab

    Regeneron UK Limited

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  41. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  42. Cemiplimab 350 MG Intravenous Solution

    Regeneron UK Limited

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  43. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  44. Cemiplimab Plus Gemcitabine

    Regeneron UK Limited

    Pancreatic Ductal Adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  45. Cemiplimab-Rwlc

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    2 trials

  46. Cemiplimab-Rwlc

    Regeneron UK Limited

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  47. Cemiplimab-Rwlc

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  48. DB-OTO

    Regeneron UK Limited

    Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

    phase 2 gene therapy active

    1 trial

Frequently asked questions

How many clinical projects does Regeneron UK have?

176 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.